Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Metabolic bone diseases: treating Paget disease: when matters more than how.

Literature DB >> 19946296

Metabolic bone diseases: treating Paget disease: when matters more than how.

Jacques P Brown.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2009 PMID： 19946296 DOI： 10.1038/nrrheum.2009.230

Source DB: PubMed Journal: Nat Rev Rheumatol ISSN： 1759-4790 Impact factor: 20.543

× No keyword cloud information.

9 in total

1. Guidelines on the management of Paget's disease of bone.

Authors: P L Selby; M W J Davie; S H Ralston; M D Stone
Journal: Bone Date: 2002-09 Impact factor: 4.398

2. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone.

Authors: W D Fraser; T C Stamp; R A Creek; J P Sawyer; C Picot
Journal: Postgrad Med J Date: 1997-08 Impact factor: 2.401

3. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

Authors: Ian R Reid; Paul Miller; Kenneth Lyles; William Fraser; Jacques P Brown; Youssef Saidi; Peter Mesenbrink; Guoqin Su; Judy Pak; Ken Zelenakas; Monica Luchi; Peter Richardson; David Hosking
Journal: N Engl J Med Date: 2005-09-01 Impact factor: 91.245

4. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).

Authors: R D Altman; C C Johnston; M R Khairi; H Wellman; A N Serafini; R R Sankey
Journal: N Engl J Med Date: 1973-12-27 Impact factor: 91.245

5. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.

Authors: P D Miller; J P Brown; E S Siris; M S Hoseyni; D W Axelrod; P J Bekker
Journal: Am J Med Date: 1999-05 Impact factor: 4.965

1 in total

Review 1. Emerging strategies and therapies for treatment of Paget's disease of bone.

Authors: Laëtitia Michou; Jacques P Brown
Journal: Drug Des Devel Ther Date: 2011-04-26 Impact factor: 4.162

1 in total

Metabolic bone diseases: treating Paget disease: when matters more than how.

1. Guidelines on the management of Paget's disease of bone.

2. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone.

3. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

4. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).

5. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.

Review 6. Goals of treatment for Paget's disease of bone.

Review 7. Diagnosis and treatment of Paget's disease of bone.

8. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone.

9. Morbidity and mortality associated with Paget's disease of bone: a population-based study.

Review 1. Emerging strategies and therapies for treatment of Paget's disease of bone.